Monday February 17, 2020

HSE begins talks on CF drug Orkambi

News relief to patients with cystic fibrosis and families

Susan Mitchell

Deputy Editor and Health Editor

28th August, 2016
Cystic fibrosis drug Orkambi

Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.

The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.

The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, but that...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Medical product supply chain could face interruption if virus continues to spread

Aaron Rogan | 1 day ago

Chief executive Paul Reid believes private care should be separate

Daniel Murray | 1 week ago

If an artist in the US can create a credible facial image of a smoker from DNA left on a discarded cigarette butt, imagine the potential power of genomic medicine, the vast awards awaiting those who possess access to genomes, and the potential for misuse where regulation of genetic information is light

Killian Woods | 1 week ago